Business
Partnership Between RenalytixAI and DaVita
Partnership Between RenalytixAI and DaVita.
About this update from Renalytix Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 5211K\n Renalytix AI PLC\n 05 January 2021\n \n \n \n \n This announcement contains inside information\n \n \n \n \n \n Renalytix AI plc\n \n \n (\"RenalytixAI\" or the \"Company\")\n \n \n \n \n \n Early Risk Identification at Core of Innovative Kidney Care Partnership Between RenalytixAI, DaVita\n \n \n \n \n \n First-of-its-kind program combines early risk assessment of kidney decline and comprehensive care management to help slow kidney disease progression, improve care coordination and reduce costs\n \n \n \n \n \n \n NEW YORK, January 5, 2021\n \n - Renalytix AI plc \n (LSE\n : RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient \n outcomes and advance value-based care\n , and \n \n \n DaVita\n \n \n (NYSE: DVA) are partnering on a program aimed at\n slowing disease progression and improving health outcomes for the nation's estimated 37 million adults with chronic kidney disease (CKD). The program is expected to improve patient outcomes and provide meaningful cost reductions for health care providers and payors by enabling earlier intervention for patients with early-stage kidney disease (stages 1, 2 and 3) through actionable risk assessments and end-to-end care management. \n \n \n \n \n \n The collaboration is expected to launch in three major markets this year. As the program expands, DaVita and RenalytixAI intend to pursue risk-sharing arrangements with health care providers and payors to drive kidney disease patient care innovation, cost efficiencies and improve quality of life.\n \n \n \n \n \n \"Almost 50% of people whose kidneys fail find out after it is too late, and we are on a mission to change that,\" said Javier Rodriguez, Chief Executive Officer for DaVita. \"Our partnership with RenalytixAI could allow us to help slow disease progression for the millions of people living with kidney disease.\"\n \n \n \n \n \n \n \"This is the first clinical-grade program that delivers advanced early-stage prognosis and risk stratification, combined with actionable care management right to the primary care level where the majority of kidney disease patients are being seen,\"\n \n said James McCullough, RenalytixAI Chief Executive Offi...